1. Home
  2. SPRO
  3. Earnings

AI Earnings Predictions for Spero Therapeutics Inc. (SPRO)

Machine learning predictions based on historical earnings data and price patterns

Latest Prediction

BUY

1-Day Prediction

+1.72%

$1.01

100% positive prob.

5-Day Prediction

+6.39%

$1.05

100% positive prob.

20-Day Prediction

+42.50%

$1.41

95% positive prob.

Price at prediction: $0.99 Confidence: 100.0% Model AUC: 1.0000 Quarter: Q3 2026

Historical Earnings Predictions

Quarter Signal 1D Return 5D Return 20D Return Confidence Actual 5D
Q3 2026 BUY +1.72% +6.39% +42.50% 100.0% Pending
Q2 2026 SELL -5.90% -9.54% -9.34% 99.9% Pending
Q1 2026 BUY -0.02% +6.60% +52.74% 99.9% +7.79%
Q3 2025 SELL -6.31% -9.73% -9.79% 100.0% -7.76%

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K BUY

Nov 12, 2026 · 100% conf.

AI Prediction BUY

1D

+1.72%

$1.01

Act: +0.60%

5D

+6.39%

$1.05

20D

+42.50%

$1.41

Price: $0.99 Prob +5D: 100% AUC: 1.000
0001193125-26-458637

EX-99.1

2 spro-ex99_1.htm

EX-99.1

EX-99.1

Spero Therapeutics Announces Third Quarter 2026 Operating Results and Provides Business Update

• SP001, an anti-CD40L antibody with potential across multiple immune-mediated diseases, advancing toward Phase 2 initiation in Immunoglobulin G4-related disease (IgG4-RD)

• Cash and cash equivalents of $107.9 million as of September 30, 2026, expected to fund operations into the second half of 2029

CAMBRIDGE, Mass., November 12, 2026 – Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for immune-mediated diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.

“We believe SP001 represents a compelling opportunity to address significant unmet medical needs across multiple immune-mediated diseases. With a strong financial position and the recent additions to our team that strengthen the capabilities needed to support our next stage of development, we believe we are well positioned to execute our clinical development strategy,” said Esther Rajavelu, President and Chief Executive Officer of Spero. “Our focus is now firmly on execution as we advance SP001 toward a Phase 2 study in IgG4-related disease, while continuing to evaluate additional indications where CD40L inhibition may benefit patients.”

Recent Business Highlights

SP001 In-Licensed from Innovent Biologics

• In July 2026, Spero in-licensed SP001 from affiliates of Innovent Biologics, Inc., obtaining exclusive worldwide rights, excluding Greater China (Mainland China, Hong Kong, Macau, and Taiwan), to research, develop, manufacture, and commercialize the antibody.

• SP001 is a third-generation, fully humanized, Fc-silent IgG1 monoclonal antibody targeting CD40L. Innovent completed Phase 1 single and multiple ascending dose studies in healthy volunteers and a Phase 1b multiple ascending dose study in patients with primary Sjögren’s disease in China. Phase 1b results were presented at the EULAR 2026 Congress.

• Spero plans to initiate a Phase 2 study for SP001 in IgG4-RD in Q2 2027. IgG4-RD is a serious, rare, chronic fibroinflammatory disease with significant treatment burden and limited therapeutic options.

$105 Million Non-Recourse, Non-Dilutive Milestone and Royalty Financing

• In July 2026, Spero closed a $105 million non-recourse, non-dilutive milestone and royalty financing with affiliates of HealthCare Royalty Partners, a business of KKR (HCRx), in exchange for a portion of anticipated Utebzi payments owed by GSK to Spero. Spero retains a 35% interest in any GSK payments remaining after the required note payments to HCRx are satisfied, preserving potential long-term upside from Utebzi.

Corporate

• In July 2026, the Company appointed Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer to lead its clinical development strategy and organization. Dr. Zack most recently served as Chief Medical Officer of Exagen Inc., following clinical leadership roles at Xencor Inc., Novartis and Amgen.

• Spero recently appointed Amy Rock, Ph.D. as Chief Regulatory and Quality Officer to lead the Company’s global regulatory strategy, quality and pharmacovigilance functions, including engagement with global health authorities to support the clinical development of SP001 in IgG4-related disease and potential additional indications.

• Spero appointed William Ho, M.D., Ph.D. to its Board of Directors and Development Committee, effective November 10, 2026. Dr. Ho brings more than twenty years of clinical development experience across oncology, allergy and immunology, including extensive experience in the translational and clinical development of novel therapeutics.

• Concurrent with Dr. Ho’s appointment, Dr. Patrick Vink stepped down from Spero’s Board following eleven years of service, during which he helped guide the Company from its IPO through its evolution into an established public company and its current strategic focus on immune-mediated diseases.

Third Quarter 2026 Financial Results

• Research and development expenses for the third quarter of 2026 were $38.2 million, compared to $8.6 million for the same period in 2025. The increase was primarily due to the $35M upfront payment made to Innovent upon the closing of the licensing agreement during the quarter.

• Spero reported a net loss of $44.3 million for the third quarter of 2026 compared to a net loss of $7.4 million for the third quarter of 2025, or a diluted net loss per share of common stock of $0.76 and $0.13, respectively.

• There was no revenue for the third quarter of 2026, compared to total revenue of $5.4 million for the third quarter of 2025.

• General and administrative expenses for the third quarter of 2026 were $3.7 million, compared to $4.2 million for the same period in 2025. The decrease was primarily due to decreased personnel costs.

• As of September 30, 2026, cash and cash equivalents

2026
Q2

Q2 2026 Earnings

8-K SELL

Aug 12, 2026 · 100% conf.

AI Prediction SELL

1D

-5.90%

$1.12

Act: +4.20%

5D

-9.54%

$1.08

20D

-9.34%

$1.08

Price: $1.19 Prob +5D: 0% AUC: 1.000
0001193125-26-346855

Transcript text not available. View on SEC.gov →

2026
Q1

Q1 2026 Earnings

8-K BUY

May 13, 2026 · 100% conf.

AI Prediction BUY

1D

-0.02%

$2.44

Act: +13.11%

5D

+6.60%

$2.60

Act: +7.79%

20D

+52.74%

$3.73

Act: +10.66%

Price: $2.44 Prob +5D: 100% AUC: 1.000
0001193125-26-221567

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.c706d217.1784384675.d6a83e90

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

About Spero Therapeutics Inc. (SPRO) Earnings

This page provides Spero Therapeutics Inc. (SPRO) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.

Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on SPRO's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.

Share on Social Networks: